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A bstract: A series o f  N -ary l and N -am in o ary l 3 -p h en y l p y rro lid in c -2 ,5 -d io n e s  w ere  syn thesized  and tested 
for an ticonvu lsan t activ ity  in the m axim um  elec tro shock  seizure (M E S ) and pentetrazol seizure th resho ld  (sc 
M et) tests. S tructu res o f  the novel com pounds w ere confirm ed  by elem ental and spectral analyses.
K eyw ords: an ticonvu lsan t ac tiv ity , p y rro !id in e -2 ,5 -d io n e , succin im ides.
In search for a  new com pounds with predic­
table anticonvulsant properties, our attention was 
draw n to a group o f  3 -pheny lpy rro lid ine-2 ,5 -d io - 
ne w ith different substituents at the nitrogen atom  
(1,2). Previous reports (3,4,5) show ed the anticon­
vulsant activity o f N -p y rid y l-3 -a ry lp y rro lid in e - 
2 ,5 -d io n e  w hich d isp layed  p ro tec tion  against 
M ES. In add ition , it w as a lso  repo rted  that 
a sig n ifican t effec t on the ac tiv ity  o f  th is co m ­
pounds being  exerted  by the p resence, position  
and ch a rac te ris tic  o f  the substituen ts  in pyrid ine 
m oiety . C rysta llo g rap h ic  in ves tiga tions (6,7) 
show ed that th e ir  pharm aco log ica l p ropertie s w e­
re connec ted  w ith the con fo rm ation . T he co n fo r­
m ation o f  pharm aco log ica lly  inactive  m o lecu les 
d iffers from  that o f  m o lecu les w ith a confirm ed  
activ ity .
This report w ill provide further structure-ac- 
tivity studies on the 3 -p h en y lp y rro lid ine-2 ,5 -d io ­
nes in w hich pyridine m oiety is replaced by the aryl 
ring w ith m ethyl o r chloro substituents [comp. 
I -V II ]  o r by the phenylam ino or diphenylam ino 
m oiety [comp. V III-X I] .
The requirem ent for NH group linking the 
pyrro lid ine- 2 ,5 -d ione  system  to the arom atic ring 
w as also investigated. A ccordingly, a series o f new 
N -ary l substituted 3 -p h en y lp y rro lid ine-2 ,5 -d io ­
nes, w as synthesized and evaluated for anticonvul­
sant activity.
As the starting materials for the synthesis 
3 -(2 -ch lo ro p h en y l)- , 3 -(3 -ch lo ro p h en y l)- , 3 - ( 4 -  
ch lo ropheny l)-,3 -(3 -fluo ropheny l)- , 3 -(3 -b ro m o - 
ph en y l)- and 3-phenylsuccin ic  acids synthesized 
by the m ethod o f  M iller et al (8 ), as m odified by 
L ange et al. (9) w ere used. The acids w ere cyclized 
to I-pheny l or l-pheny lam ino -3 -pheny lpy rro lid i- 
n e-2 ,5 -d io n e  derivatives [I—XI] by heating them at
ca. 190°-200°C for 1.5-2 h w ith appropriate aryla- 
m ine (Schem e 1) o r w ith arylhydrazine.
E X PE R IM E N T A L  
C hem istry
M elting points (°C) w ere uncorrected, 'H  
N M R  spectra [I -X I] w ere recorded in CD CL 
solution by using TM S as an internal standard 
(B ruker VM 250 M H z N M R  Spectrom eter). The 
chrom atography was perform ed w ith M erck silica 
gel G F 2 5 4  precoated T LC  sheets using the follow ing 
developing system s: A -  chloroform : aceton (9:1), 
B -  chloroform : methanol: acetic acid (60: 10: 5). 
Spots were detected by their absorption under UV 
light and visualization w ith 0.05 mol L in 10% 
HC1.
1-P heny l and l-pheny lam ino -3 -pheny lpy rro - 
lid in e - 2 ,5 -d ione  derivatives [I -  XI].
G eneral procedure.
An appropriate arylam ine or arylhydrazine 
(0.02 mole) w ere dissolved in 25 ml o f w ater and 
appropriate 2 -substitu te  succinic acid (0 . 0 2  mole) 
w as gradually added. The m ixture was heated in oil 
bath with sim ultaneous distillation o f water. A fter 
com plete rem oval o f water, the tem perature o f the 
reaction m ixture was raised up to 190-200l’C and 
m aintained for 1.5 h. The crude product was 
recrystallized from  ethanol.
Physicochem ical data, 'H  NM R data, yields 
and elem entary analysis results o f the com pounds 
synthesized w ere presented in Table la , b.
P harm acology
C om pounds I-X I  w ere pharm acologically 
pre-evaluated  within the A ntiepileptic D rug D eve­
lopm ent (ADD) Program , Epilepsy Branch, Neuro-
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Schem e 1.
S chem e 2.
logical D isorders Program  National Institutes o f  the 
N eurological and C om m unicative D isorders and 
Stroke (N IN CD S), by using the testing procedures 
described elsew here (10,11). Phase I studies invol­
ved three tests: m axim um  electroshock seizure 
(M ES), subcutaneous pentylenetetrazole (sc M et), 
and the neurotoxicity (TO X ). The M ES test is 
a m odel for generalized ton ic-c lon ic  seizures. In 
this test, an electrical stim ulus o f  0.2 s in duration 
(50 mA in m ice at 60 Hz) is delivered via corneal 
electrodes. M ice are tested for 30 min. and 4 h with
the follow ing doses: 30, 100, 300 m g/kg o f  test 
com pound (12).
The scM et is a m odel for com pounds that raise 
a  seizure threshold. In scM et test a dose o f m etrazol 
is 85m g/kg in mice. T his produces clonic seizures 
during a period o f  at least 5 seconds in 97%  o f 
tested anim als. T he m etrazol is adm inistrated sub- 
cutaneously. The test com pounds are adm inistrated 
intraperitoneally , suspended in 0.5%  m ethylcellu- 
lose at the doses o f 30, 100, 300 m g/kg (13). 
N eurotoxicity, induced by a test com pound, is
S y n th e s is  a n d  a n t ic o n v u ls a n t  p ro p e r t ie s  o f  n e w  1 -p h e n y l a n d .. 211






Analysis cal./found 'H NMR/CDCF/5 R,/
solvent%C %H %N










2.53 (3H, s, CH-0, 2.75-2.90 (IH , d, imide), 
3.35-3.42 (1H, q, imide), 4 .0 8 A 4 0  (1H, q, 
imide), 7.10-7.60 (9FI, m, arom)
0.67A
0.82B










2.15 and 2.19 (3H, 2 s, CH,), 2.96-3.00 (1H, 
td, imide), 3.40-3.51 (1H, dq, imide), 4 .20- 
4.32 (1H, q, imide), 6.99-7.40 (7H, m, arom)
0.80A
0.79B










2.32 (3H, s, CHj), 2.74-2.83 (1H, d, imide), 
3.14-3.24 (1H, d, imide), 3.97-4.02 (1H, q, 














2.18 and 2.21 (H, 2s, C H ,), 2 .97 -3 .04  
(1H, td, im ide), 3 .3 8 -3 .5 0  (1H, dq, im i­














2.92-3.00 (1H, dd, imide), 3.33-3.42 (1H, q, 














2 .15 -2 .18  (3H, d, CH.,), 2 .9 2 -2 .9 6  and 
3 .0 1 -3 .0 6  (1H, dt, im ide), 3 .33 -3 .48  (1H, 
dq, imide), 4.14-4.24 (1H, q, imide), 7 .20- 
7.48 (8H, m, arom)
0.80A
0.85B










2.15-2.18 (3H, 2s, CH,), 2.92-3.05 (IH , dq, 
imide), 3.23-3.49 (1H, dq, imide), 4.14—4.24 
(1H, dq, imide), 7.07-7.50 (8H, m, arom)
0.72A
0.83B






Analysis cal./found 'H NMR/CDCl.,/8 Rr/
solvent%C %H %N










2.89-3.00 (1H, dd, CHum ide), 3.24-3.39 
(1H, dd, CH2imide), 4.09-4.17 (1H, q, CH 
imide), 7.09-7.42 (15H, m, arom)
0.73A
0.84B










2.91-2.94 (1H, dd, CH,imide), 3.27-3.41 
(1H, dd, CHńmide), 4.37-4.45 (1H, q, CH 














2.91-2.94 (1H, dd, CH2imide), 3.27-3.41 
(1H, dd, CHjimide), 4.37-4.45 (1H, q, CH 














2.90-3.03 (IH , m, imide), 3.26-3.35 (1H, m, 
imide), 4.34-4.42 (IH , m, imide), 6.69-6.80 
(2H, m, arom), 7.13-7.51 (7H, m, arom), 
8.44 (IH , s, NH)
0.69A
0.87B
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mg/kg 0.5 h 4 h 0.5 h 4 h 0.5 h 4 h class
30 0/1 0/1 0/1 0/1 0/4 0/2
I 100 1/3 0/3 0/1 0/1 0/8 0/4 1
300 1/1 0/1 4/5 0/1 0/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
II 100 0/3 0/3 0/1 0/1 0/8 0/4 3
300 0/1 0/1 0/1 0/1 0/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
III 100 0/3 0/3 0/1 0/1 0/8 0/4 2
300 1/1 0/1 1/1 0/1 0/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
IV 100 0/3 0/3 0/1 0/1 0/8 0/4 3
300 0/1 0/1 0/1 0/1 0/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
V 100 0/3 0/3 0/1 0/1 0/8 0/4 3
300 0/1 0/1 0/1 0/1 0/4 0/2
30 1/4 0/1 0/1 0/1 0/4 0/2
VI 100 3/3 0/3 0/1 0/1 0/8 0/4 1
300 1/1 0/1 1/1 0/1 0/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
VII 100 1/3 0/3 0/1 0/1 0/8 0/4 1
300 1/1 0/1 3/5 0/1 1/4 0/2
* T onic extension
“'M axim al elec troshock  test (num ber o f  an im als p ro tec ted /num ber o f  an im als tested) 
h,S ubcu taneous pen ty lenete trazo le  test
clR otorod toxicity  (num ber o f  an im als exh ib iting  tox ic ity /num ber o f  an im als tested) 
c’T he classification  is as follow s:
1 -an ticonvu lsan t activ ity  at doses 100 m g/kg o r less
2 -an lico n v u lsan t ac tiv ity  at doses grea ter than 100 m g/kg
3 -co m p o u n d  inactive at 300  m g/kg
T ab le 2b. A nticonvu lsan t S creen ing  P ro jec t (A SP ) P hase 1 T est results in m ice (com p. V I I I -X I )
Comp. Dose
Activity
Tox° A S P1’
MES"’ sc Met1”
mg/kg 0.5 h 4 h 0.5 h 4 h 0.5 h 4 h class
30 0/1 0/1 0/1 0/1 0/4 0/2 *
V III 100 0/3 0/3 0/1 0/1 0/8 0/4 2
300 0/1 0/1 1/5 0/1 0/2 0/2
30 0/1 0/1 0/1* 0/1 0/4 0/2
IX 100 0/3 0/3 0/1 0/1 0/8 0/4 2
300 0/1 0/1 1/5 0/1 0/4 0/2
30 0/1 0/1 0/1* 0/1 0/4 0/2
X 100 0/3 0/3 0/1 0/1 0/8 0/4 3
300 0/1 0/1 0/1 0/1 1/4 0/2
30 0/1 0/1 0/1 0/1 0/4 0/2
XI 100 0/3 0/3 0/1 0/1 0/8 0/4 3
300 0/1 0/1 0/1 0/1 0/4 0/2
* T onic extension
;l,M axim al electroshock  test (num ber o f  an im als p ro tec ted /num ber o f  an im als tested) 
h,Subcu taneous pen ty lenete trazo le  test
c>R otorod tox icity  (num ber o f  an im als exh ib iting  tox ic ity /num ber o f  an im als tested) 
cT h e  classification  is as follow s:
1 -an ticonvu lsan t ac tiv ity  at doses 100 m g/kg o r less
2 -an tico n v u lsan t ac tiv ity  at doses g rea ter than 100 m g/kg
3 -co m p o u n d  inactive at 300  m g/kg
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detected in m ice using a rotorod test. U ntreated 
control mice, when placed on a 6 r.p.m . rotation 
rod can m aintain their equilibrium  for a prolonged 
time. N eurotoxicity is indicated by the inability of 
a mouse m aintaining equilibrium  for one m inute in 
each o f  the three successive trials (14). R esults are 
given in Table 2a, b.
R ESU LTS
In a series o f l,3 -d ip h en y lp y rro lid in e-2 ,5 - 
diones [I—VII] com pounds I, III, VI, and VII 
show ed som e anticonvulsant properties in phase 
I o f screening project. The l-(2 -m eth y lp h e - 
n y l)-3 -pheny lpy rro lid ine-2 ,5 -d ione  I and three 
analogues o f this com pound III, VI, VII were 
found to be effective in this screening procedure. 
T he m ost potent in M ES test w as l- (2 -m e th y l-  
pheny l)-3 -(3 -b ro m o p h en y l)p y rro lid in e -2 ,5 -d io n e  
VI, w hich protected all anim als after 0.5 h at 30, 
100 and 300 m g/kg. The l- (4 -m e th y lp h e n y l)-3 -  
(3 -fluoropheny l)pyrro lid ine-2 ,5 -d ione  III had an­
ticonvulsant properties but only at a dose o f 300 
m g/kg. T his com pounds in the scM et test at a dose 
o f 300 m g/kg show ed m arginal anticonvulsant 
properties. Som e activity was recorded in the 
scM et test also for com pounds I, VI, VII (active at 
300 m g/kg at 4h).
The presence and position o f the m ethyl group 
in N -ary l moiety appears to be essential for the 
anticonvulsant activity in this group o f  com pounds. 
The m ost potent in M ES test w ere com pounds with 
the methyl group in position 2 or 4  o f  the 1-phenyl 
ring v/z., I, VI and V II. The change o f  the brom  
atom for chlor substituents on the 3-pheny l ring in 
com pounds IV and V made them  inactive. This 
effect m aybe is connected with low er lipophilicity. 
The m ethylene bridge in com pound III decreased 
the activity. Introduction o f the second substituents 
(-C1) in the 4 -position  o f  the 1-phenyl ring led to 
an inactive com pound II.
In a series o f  1-phenylam ino derivatives X, 
XI w ere devoid o f  anticonvulsant activity. C om ­
pounds V III, IX w ere active only in the scM et test 
at 0.5 h using 300 mg/kg. This result suggests that 
the NH group, linking I-pheny l ring w ith 3 -pheny- 
lpy rro lid ine-2 ,5 -d ione  m oiety, is probably not ne­
cessary for anticonvulsant activity.
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